Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It focuses on harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.
相关临床试验
3
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2018
进行中（未招募）
1
33.3%
招募中
1
33.3%
终止
1
33.3%
暂无批准数据
- Century Therapeutics appointed Dr. Han Lee and Dr. Martin Murphy to its Board of Directors to provide strategic oversight as the company advances its iPSC-derived cell therapy programs. - Dr. Lee brings extensive capital formation and corporate development experience from leadership roles at ImmPACT Bio, Neogene Therapeutics, and Arcellx. - Dr. Murphy contributes significant life science investment expertise as co-founder of Syncona Limited and current board positions at multiple biotech companies. - The appointments come as Century focuses on bringing CNTY-813, a potential curative treatment for type 1 diabetes, and other pipeline candidates closer to clinical trials.
- Century Therapeutics announced CNTY-813, an iPSC-derived beta islet therapy engineered with Allo-Evasion™ 5.0 technology designed to provide durable glucose control without chronic immunosuppression for Type 1 diabetes patients. - Preclinical data demonstrate rapid reversal of diabetes and sustained normoglycemia in diabetic mouse models, with significant glucose-stimulated insulin secretion and detectable human C-peptide production. - The company plans to initiate IND-enabling studies by year-end 2025 and submit an IND application to the FDA as early as 2026 for this potentially curative therapy. - The therapy addresses a significant unmet need for approximately 9 million Type 1 diabetes patients worldwide, with the U.S. healthcare system spending $6-8 billion annually on insulin treatments.
- TC Biopharm's OmnImmune is advancing through a pivotal Phase 2/3 trial for acute myeloid leukemia, representing one of the most advanced gamma delta T cell therapies globally. - The company's TCB008 candidate achieved complete molecular remission in a relapsed patient with detectable minimal residual disease after just two doses in the Phase 2 ACHIEVE trial. - More than 25 gamma delta T cell therapies are currently in clinical development worldwide, with the highest phase reaching Phase 2/3, though no therapies have achieved commercial availability as of June 2025. - The field remains predominantly focused on hematologic malignancies, with fewer programs targeting solid tumors due to complex tumor microenvironments and immune evasion mechanisms.
• Century Therapeutics' CNTY-101, an iPSC-derived CD19 CAR-iNK cell therapy, will be assessed in a Phase 1/2 trial for B-cell mediated autoimmune diseases. • The CARAMEL trial, led by Professors Schett and Mackensen, will evaluate CNTY-101's safety and efficacy in systemic lupus erythematosus, lupus nephritis, and other conditions. • CNTY-101 is engineered with six gene edits to target and eliminate B cells, which are crucial in autoantibody production and lupus disease activity. • The trial, sponsored by Friedrich-Alexander University Erlangen-Nürnberg, is set to commence in mid-2025, pending clinical trial application approval.
